PET and SPECT imaging in parkinsonian syndromes

Pet and Spect in Neurology

Volumn , Issue , 2014, Pages 619-638

  Leenders, Klaus L ^b   Niethammer, Martin ^a   Allen, Patricia J ^a   David, Eidelberg ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940720218     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-54307-4_28     Document Type: Chapter

References (97)

1. Abe K, Takanashi M, Yanagihara T (2000) Fatigue in patients with Parkinson’s disease. Behav Neurol 12:103-106
2. Bartels AL, Leenders KL (2007) Neuroinflammation in the pathophysiology of Parkinson’s disease: Evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord 22:1852-1856
3. Bartels AL, de Jong BM, Giladi N, Schaafsma JD, Maguire RP, Veenma L, Pruim J, Balash Y, Youdim MB, Leenders KL (2006) Striatal dopa and glucose metabolism in PD patients with freezing of gait. Mov Disord 21:1326-1332
4. Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL (2010) [11C]- PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease? Parkinsonism Relat Disord 16:57-59
5. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 45:182-184
6. Benamer H, Grosset D (2009) Vascular parkinsonism: A clinical review. Eur Neurol 61:11-15
7. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692-698
8. Benamer H.T., Oertel W.H., Patterson J., Hadley D.M., Pogarell O., Hoffken H., Gerstner A., Grosset D.G. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3-month observations. Mov Disord 18:977-984
9. Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol 248:684-689
10. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA (1997) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62: 133-140
11. Bosman T, Van Laere K, Santens P (2003) Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson’s disease. Eur J Nucl Med Mol Imaging 30:16-24
12. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991-998
13. Cordato N, Pantelis C, Halliday G, Velakoulis D, Wood S, Stuart G, Currie J, Soo M, Olivieri G, Broe G, Morris J (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125:789-800
14. Davie C, Wenning G, Barker G, Tofts P, Kendall B, Quinn N, McDonald W, Marsden C, Miller D (1995) Differentiation of multiple system atrophy from idiopathic Parkinson’s disease using proton magnetic resonance spectroscopy. Ann Neurol 37:204-210
15. Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Doring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Kollensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Bottger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K (2010) Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25:97-1075
16. Eckert T., Eidelberg D. (2005) Neuroimaging and therapeutics in movement disorders. NeuroRx 2:361-371
17. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, Eidelberg D (2005) FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26:912-921
18. Eckert T, Van Laere K, Tang C, Lewis DE, Edwards C, Santens P, Eidelberg D (2007) Quantification of Parkinson’s disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 34:496-501
19. Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, Feigin A, Eidelberg D (2008) Abnormal metabolic networks in atypical parkinsonism. Mov Disord 23:727-733
20. Eidelberg D (2009) Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci 32:548-557
21. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E et al (1993) Striatal hypometabolism distinguishes nigrostriatal degeneration from Parkinson’s disease. Ann Neurol 33:518-527
22. Eidelberg D, Moeller J, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S et al (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783-801
23. El Fakhri G, Habert MO, Maksud P, Kas A, Malek Z, Kijewski MF, Lacomblez L (2006) Quantitative simultaneous (99m)Tc-ECD/123I-FP-CIT SPECT in Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 33:87-92
24. Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL (2006) Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging 33:200-209
25. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL (2009) Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging 36:454-462
26. Federico F, Simone I, Lucivero V, Iliceto G, De Mari M, Giannini P, Mezzapesa D, Tarantino A, Lamberti P (1997) Proton magnetic resonance spectroscopy in Parkinson’s disease and atypical parkinsonian disorders. Mov Disord 12:903-909
27. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen J, Dhawan V, Eidelberg D (2007) Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain 130:2858-2867
28. Gaenslen A, Gasser T, Berg D (2008) Nutrition and the risk for Parkinson’s disease: Review of the literature. J Neural Transm 115:703-713
29. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, Turkheimer F, Good CD, Mathias CJ, Quinn N, Schwarz J, Brooks DJ (2003) [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61:686-689
30. Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K, Brooks DJ (2004) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 19:1221-1226
31. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006a) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404-412
32. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ (2006b) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 21:89-93
33. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD (2002) Differentiating multiple system atrophy from Parkinson’s disease: Contribution of striatal and midbrain MRI volumetry and multitracer PET imaging. J Neurol Neurosurg Psychiatry 73:517-523
34. Gilman S, Wenning G, Low P, Brooks D, Mathias C, Trojanowski J, Wood N, Colosimo C, Durr A, Fowler C, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670-676
35. Habeck C, Foster N, Perneczky R, Kurz A, Alexopoulos P, Koeppe R, Drzezga A, Stern Y (2008) Multivariate and univariate neuroimaging biomarkers of Alzheimer’s disease. Neuroimage 40:1503-1515
36. Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW, Neumaier B, Ludolph AC, Reske SN, Landwehrmeyer GB (2004) Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov Disord 19:817-821
37. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D (2007) Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage 34: 714-723
38. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D (2008) Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70:1470-1477
39. Hughes A, Daniel S, Kilford L, Lees A (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
40. Hughes A, Daniel S, Ben-Shlomo Y, Lees A (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861-870
41. Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F, Lang AE (1999) SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 52:1206-1214
42. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106:518-526
43. Ishizawa K, Dickson DW (2001) Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neurol Exp Neurol 60:647-657
44. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neurol Exp Neurol 63:43-52
45. Josephs K, Dickson D (2003) Diagnostic accuracy of progressive supranuclear palsy in the society for progressive supranuclear palsy brain bank. Mov Disord 18:1018-1026
46. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO (2000) Upregulation of putaminal dopamine D2 receptors in early Parkinson’s disease: A comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med 41:65-70
47. Kanazawa M., Shimohata T., Terajima K., Onodera O., Tanaka K., Tsuji S., Okamoto K., Nishizawa M. Quantitative evaluation of brainstem involvement in multiple system atrophy by diffusion-weighted MR imaging. J Neurol 251:1121-1124
48. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, Lang AE (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17:303-331
49. Klaffke S, Kuhn AA, Plotkin M, Amthauer H, Harnack D, Felix R, Kupsch A (2006) Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 21:1724-1727
50. Klein RC, de Jong BM, de Vries JJ, Leenders KL (2005) Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 20:1021-1030
51. Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L (2004) Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 31:1631-1638
52. Leenders KL (2003) Significance of non-presynaptic SPECT tracer methods in Parkinson’s disease. Mov Disord 18(Suppl 7):S39-S42
53. Linder J, Birgander R, Olsson I, Riklund K, Larsson A, Edstrom M, Stenlund H, Forsgren L (2009) Degenerative changes were common in brain magnetic resonance imaging in patients with newly diagnosed Parkinson’s disease in a population-based cohort. J Neurol 256:1671-1680
54. Litvan I (2003) Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord 18(Suppl 6):S43-S50
55. Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, McKee A, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y (1997) What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 54:937-944
56. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D (2007) Abnormal metabolic network activity in Parkinson’s disease: Test-retest reproducibility. J Cereb Blood Flow Metab 27:597-605
57. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, Van Dyck C, Hoffer PB, Innis R.P. (1996) [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46:231-237
58. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J (2001) [123I]beta- CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 57:2089-2094
59. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Hoffken H, Gerstner A, Grosset DG (2009) Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 24:500-508
60. Minnerop M, Specht K, Ruhlmann J, Schimke N, Abele M, Weyer A, Wullner U, Klockgether T (2007) Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy-a comparison between clinical subtypes and correlations with clinical parameters. Neuroimage 36:1086-1095
61. Nicoletti G, Lodi R, Condino F, Tonon C, Fera F, Malucelli E, Manners D, Zappia M, Morgante L, Barone P, Barbiroli B, Quattrone A (2006) Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson’s disease and progressive supranuclear palsy. Brain 129:2679-2687
62. Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO (2000) Progression in Parkinson’s disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47:804-808
63. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168-175
64. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M (2006) Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27:402-409
65. Papp M, Kahn J, Lantos P (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (nigrostriatal degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79-100
66. Paviour D, Price S, Stevens J, Lees A, Fox N (2005) Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 64:675-679
67. Perju-Dumbrava LD, Kovacs GG, Pirker S, Jellinger K, Hoffmann M, Asenbaum S, Pirker W (2012) Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy. Mov Disord 27:65-71
68. Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, Brucke T. (2000) [123I] beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15:1158-1167
69. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Brucke T (2002) Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: A longitudinal beta-CIT SPECT study. Mov Disord 17:45-53
70. Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, Wernecke KD, Kupsch A, Felix R, Venz S (2005) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: Study on 72 patients. J Neural Transm 112:677-692
71. Poston KL, Eidelberg D (2009) Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis 35:141-147
72. Poston K, Tang C, Eckert T, Dhawan V, Frucht S, Vonsattel J, Fahn S, Eidelberg D (2012) Network correlates of disease severity in multiple system atrophy. Neurology 78:1237-1244
73. Scherfler C., Seppi K., Donnemiller E., Goebel G., Brenneis C., Virgolini I., Wenning G.K., Poewe W. (2005) voxel-wise analysis of [123i]beta-cit spect differentiates the parkinson variant of multiple system atrophy from idiopathic parkinson’s disease. Brain 128:1605-1612
74. Schott J, Williams D, Butterworth R, Janssen J, Larner A, Holton J, Rossor M (2007) Shunt responsive progressive supranuclear palsy? Mov Disord 22:902-903
75. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C et al (1995) Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38:589-598
76. Seppi K, Schocke M (2005) An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 18:370-375
77. Soliveri P, Monza D, Paridi D, Radice D, Grisoli M, Testa D, Savoiardo M, Girotti F (1999) Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 53:502-507
78. Spetsieris P, Ma Y, Dhawan V, Eidelberg D (2009) Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage 45:1241-1252
79. Spiegel J, Mollers MO, Jost WH, Fuss G, Samnick S, Dillmann U, Becker G, Kirsch CM (2005) FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov Disord 20:552-561
80. Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G (2000) Measuring the progression of idiopathic Parkinson’s disease with [123I] beta-CIT SPECT. J Neural Transm 107:543-552
81. Sudmeyer M, Antke C, Zizek T, Beu M, Nikolaus S, Wojtecki L, Schnitzler A, Muller HW (2011) Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: A multidimensional statistical approach. J Nucl Med 52:733-740
82. Tang C, Poston K, Dhawan V, Eidelberg D (2010a) Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci 30:1049-1056
83. Tang C, Poston K, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel J, Fahn S, Eidelberg D (2010b) Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol 9:149-158
84. Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL (2010) Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 25:2395-2404
85. Teune LK, Renken RJ, Mudali D, De Jong BM, Dierckx RA, Roerdink JB, Leenders KL (2013) Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord 28: 547-551
86. Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, Vandenberghe W, Verbruggen A, Dom R (2006) Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med 47:384-392
87. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1023-1032
88. Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, Tromp SC, van Kroonenburgh MJ, Weber WE (2008) Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 59:258-266
89. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D (2003) Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes. Neurology 60:74-77
90. Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R (2004) Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 63:504-509
91. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, Aiba I, Abe Y, Tamakoshi A, Doyu M, Hirayama M, Sobue G (2002) Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients. Brain 125:1070-1083
92. Wenning G, Stefanova N (2009) Recent developments in multiple system atrophy. J Neurol 256:1791-1808
93. Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W (1998) 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson’s disease. Mov Disord 13:438-445
94. Williams D, Lees A (2009) Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270-279
95. Williams D., De Silva R., Paviour D., Pittman A., Watt H., Kilford L., Holton J., Revesz T., Lees A. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 128:1247-1258
96. Williams D, Holton J, Strand K, Revesz T, Lees A (2007) Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy. Mov Disord 22:2235-2241
97. Winikates J., Jankovic J. (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56:98-102